A5101894418- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Breast Cancer Treatment Studies
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Monoclonal and Polyclonal Antibodies Research
- Advanced materials and composites
- Cancer, Lipids, and Metabolism
- Lung Cancer Treatments and Mutations
- Cancer Diagnosis and Treatment
- Endometrial and Cervical Cancer Treatments
- Cancer Risks and Factors
- Multiple Myeloma Research and Treatments
- Cancer Genomics and Diagnostics
- Powder Metallurgy Techniques and Materials
- Cancer-related cognitive impairment studies
- Additive Manufacturing Materials and Processes
- Metabolism and Genetic Disorders
- Nitric Oxide and Endothelin Effects
- Ovarian cancer diagnosis and treatment
- Peptidase Inhibition and Analysis
- Hormonal Regulation and Hypertension
- Sarcoma Diagnosis and Treatment
- Chemotherapy-related skin toxicity
Sapporo Medical University
2016-2024
Kariya Toyota General Hospital
2023-2024
Saitama Red Cross Hospital
2014-2023
Saitama Cancer Center
2006-2023
National Hospital Organization Saitama Hospital
2017-2023
Yokkaichi Municipal Hospital
2022
National Cancer Center Hospital East
2016-2019
Okayama University Hospital
2016-2019
Aichi Cancer Center
2016-2019
University of Tokyo Hospital
2019
Adjuvant trastuzumab monotherapy has not been compared with + chemotherapy. We investigated the relative value of for older patients breast cancer.This study was an open-label, randomized controlled a treatment selection design in which noninferiority criterion predefined. Patients aged 70-80 years surgically treated human epidermal growth factor receptor 2-positive invasive cancer received or The primary end point disease-free survival (DFS) assessment prespecified hazard ratio (HR),...
The developmental time and thermal threshold for temperature-dependent sex determination (TSD), gender differences in temperature sensitivity, the fertility of thermally reversed fish, effect on expression two major determination/differentiation genes <i>(DMY</i>/<i>DMRT1bY</i> <i>DMRT1)</i> were examined Hd-rR strain medaka, <i>Oryzias latipes</i>. Fertilized eggs exposed from either shortly after fertilization (8–16 cells; embryonic stages...
The effect of tamoxifen, an antiestrogenic agent, on lipid metabolism was studied in postmenopausal patients with breast cancer who received the drug for postoperative adjuvant treatment following mastectomy. To measure total cholesterol and triglyceride concentrations, fasting blood samples were collected before 2 months after initiation tamoxifen therapy from 16 satisfied study criteria. All normolipidemic administered. Control obtained hypertriglyceridemia free cancer. Marked observed 3...
The purpose of this study was to gain a better understanding the transport mechanism pitavastatin, novel synthetic HMG-CoA reductase inhibitor. Experiments were performed using oocytes Xenopus laevis expressing several solute carrier (SLC) transporters and recombinant membrane vesicles human ABC transporters. acid form pitavastatin shown be substrate for OATP1, OATP2, OATP8, OAT3 NTCP, rat Oatp1 Oatp4 with relatively low K(m) values. In contrast, these SLC not involved in uptake lactone...
No clinical evidence on the efficacy and safety of eribulin monotherapy has been obtained by a prospective study in patients with metastatic breast cancer (MBC) who had well-defined taxane resistance. The present Phase II, multicenter, single-arm, open-label aimed to obtain evidence. Japanese female patients, aged 33–74 years metastasis taxane-resistant histopathologically confirmed cancer, received mesylate 1.4 mg/m2 (equivalent 1.23 [expressed as free base]) 2- 5-min intravenous infusion...
To evaluate the addition of ofranergene obadenovec (ofra-vec, VB-111), a novel gene-based anticancer targeted therapy, to once week paclitaxel in patients with recurrent platinum-resistant ovarian cancer (PROC).
Background: The aim of this study was to examine the association serum isoflavones, adiponectin, and insulin levels with ovarian cancer risk. Materials Methods: We gathered cases histologically confirmed epithelial at Sapporo Medical University Hospital from October 2010 September 2012. Potential controls were recruited female inpatients without any history or diabetes mellitus in different wards same hospital over period time. Serum measured order estimate associations risk a case-control...
Abstract Background A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine molecular‐targeted drugs. Thus, it is essential identify genomic alterations and molecular features recommend effective targeted medicines regardless of the tumor site. Nevertheless, takes considerable expertise targets primary‐sequencing data order provide drug recommendations. The Molecular Tumor Board (MTB) denotes a platform that integrates...
510 Background: The relative value of trastuzumab (H) monotherapy as an adjuvant treatment compared to the standard combination with chemotherapy (CT) is not clear for elderly breast cancer (BC) patients (pts). Methods: We randomly assigned pts over 70 years (yrs) old HER2-positive invasive BC who received curative surgery into either H (H group) or plus CT (H+CT selected from pre-specified regimens (PTX/DTX/TC/AC/EC/FEC/CMF/TCb [CBDCA]). primary endpoint was disease-free survival (DFS), and...
Cobalt-chromium-molybdenum (Co-Cr-Mo) alloys are used for biomedical implants such as artificial joints because they have excellent wear and corrosion resistance biocompatibility. Electron-beam melting (EBM) is a type of additive manufacturing technique metals. We EBM to fabricate 20 rods Co-Cr-Mo alloy with height 160 mm arranged in 4 × 5 matrix observed the phase constitution middle part (at 80 mm) by scanning electron microscopy-electron backscatter diffraction. found that center...
We report findings on quality of life (QoL) in the RESPECT trial, which compared adjuvant trastuzumab monotherapy with plus chemotherapy older patients human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC).Patients age 70-80 years 2-positive surgically treated were randomly assigned to receive (T) or (T + C). QoL was assessed using Functional Assessment Cancer Therapy-General (FACT-G), Philadelphia Geriatric Center Morale Scale, Hospital Anxiety and Depression Patient...
It has been reported that treatment with uracil-tegafur (UFT) shown significantly better survival and relapse-free (RFS) than surgery alone. Therefore, we compared UFT a combination therapy of cyclophosphamide, methotrexate, fluorouracil (CMF) in patients who had undergone curative for axillary lymph node-positive breast cancer. A total 377 stage I, II, or IIIA disease were registered from September 1996 through July 2000 randomly assigned to either 6 cycles CMF 2 years UFT. In both arms,...
<b><i>Objective:</i></b> The aim of this study was to investigate the correlation between human epidermal growth factor receptor 2 (HER2)-related biomarkers and treatment outcomes using lapatinib plus capecitabine (LC) evaluate influence estrogen (ER) status in trastuzumab-refractory HER2-positive advanced breast cancer. <b><i>Method:</i></b> Eighty patients were enrolled study. Total HER2, p95HER2, total HER3 expression quantified VeraTag...
Summary Background This large-scale study was conducted to evaluate the safety and effectiveness of eribulin for treatment inoperable or recurrent breast cancer in real-world settings Japan. Methods Between July December 2011, eligible patients with receiving first time were centrally registered observed 1 year. Eribulin administered intravenously (1.4 mg/m 2 ) on days 8 every 3-week cycle. The primary endpoint frequency intensity adverse drug reactions (ADRs). Secondary endpoints included...
Summary Purpose To examine the efficacy and safety of triple therapy with eribulin, trastuzumab, pertuzumab in patients HER2-positive metastatic breast cancer (MBC) who never received any prior first-line metastatic/advanced setting. Methods Eribulin 1.4 mg/m 2 (days 1 8), trastuzumab 8 mg/kg over 90 min 6 30 min, 840 mg/body 60 420 were administered intravenously 21-day cycles. Results 25 women (median age, 57 years [range, 41–75 years]) a median 10 cycles (range, 0–34 cycles); 24 had...
To gain a better understanding of drugdrug interaction between various medicinal substances and statins, in vitro experiments using human hepatic microsomes were performed. The metabolic clearance atorvastatin (CAS 134523-00-5) was about 32 µl /min/mg protein, some 15-fold greater than that pitavastatin 147526-32-7). On co-incubation with several substances, inhibition negligible microsomes. However, remarkable noted the presence substances. intrinsic lactone 20-fold its acid form, whereas...
In this study, the interaction of interferon-gamma-(IFN-gamma) and inducible nitric oxide synthase (iNOS)-producing cells in human radicular cysts were investigated.Inflamed periapical tissues obtained from patients at time endodontic surgical treatments cut into two pieces. After fixing with acetone or 4% paraformaldehyde phosphate-buffered saline, 5-m-thick paraffin cryostat sections prepared. The inflamed evaluated histologically haematoxylineosin stains. specimens diagnosed as then...